ÂÜÀòÂÒÂ×

Roy Maute is currently serving as the Chief Scientific Officer at Pheast Therapeutics, where Roy focuses on targeting macrophage checkpoints to activate the immune system against cancer cells. Prior to their current role, Roy held positions at Gilead Sciences, Forty Seven Inc., Ab Initio Biotherapeutics, Inc., Stanford University School of Medicine, Columbia University Irving Medical Center, and the Ernest Gallo Clinic and Research Center. Roy has a Doctor of Philosophy (PhD) in Genetics from Columbia University and a Bachelor of Arts (B.A.) in Molecular and Cell Biology from the University of California, Berkeley.